Low-dose statin and ezetimibe for early heart disease
This study tests whether combining a low-dose statin with ezetimibe is safe and effective for people who have very early signs of plaque buildup in their arteries but are not yet at high risk. The goal is to see if this combination can prevent heart disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 79 years old
- You have very early signs of artery plaque (like a small amount of calcium or a minor narrowing) confirmed by a heart scan or ultrasound
- Your LDL cholesterol is high enough to qualify for treatment under national guidelines, based on your risk factors
- You have not been diagnosed with diabetes
- You do not have severe kidney disease or liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.
This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.
This trial studies whether high-intensity statin plus ezetimibe can improve heart health in people who do not have symptoms but have calcium buildup in their heart arteries. It may help lower cholesterol and reduce future heart risks for the right participants.
This trial tests whether ezetimibe, a cholesterol-lowering drug, changes the bacteria in your gut. It may help people with heart disease or high cholesterol who are already on a statin.
This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
Hear when a new Atherosclerosis Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.